CHRISTIE BALLANTYNE to Middle Aged
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Middle Aged.
Connection Strength
5.480
-
Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025 Jan-Feb; 19(1):28-38.
Score: 0.060
-
Intensive Lifestyle Intervention, Cardiac?Biomarkers, and Cardiovascular?Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study. J Am Coll Cardiol. 2025 Feb 11; 85(5):489-500.
Score: 0.060
-
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024 Jul 01; 9(7):620-630.
Score: 0.058
-
Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1. JAMA Cardiol. 2024 Jun 01; 9(6):497-506.
Score: 0.058
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
Score: 0.058
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
Score: 0.054
-
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 04 25; 81(16):1553-1564.
Score: 0.053
-
Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. Atherosclerosis. 2023 02; 367:15-23.
Score: 0.053
-
Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
Score: 0.050
-
Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
Score: 0.046
-
Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. J Am Heart Assoc. 2020 07 07; 9(13):e015405.
Score: 0.044
-
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
Score: 0.042
-
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019 06 04; 139(23):2642-2653.
Score: 0.041
-
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 01 03; 380(1):11-22.
Score: 0.040
-
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 01; 280:109-117.
Score: 0.040
-
Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018 10; 16(10):1964-1972.
Score: 0.039
-
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 10; 277:195-203.
Score: 0.038
-
Improving Outcomes After Myocardial Infarction in the US Population. J Am Heart Assoc. 2018 02 17; 7(4).
Score: 0.038
-
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). Atherosclerosis. 2018 01; 268:12-18.
Score: 0.037
-
The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis. 2017 07; 262:131-137.
Score: 0.036
-
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
Score: 0.036
-
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.
Score: 0.035
-
Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. Circulation. 2017 02 21; 135(8):720-723.
Score: 0.035
-
25-Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2016 11 07; 5(11).
Score: 0.034
-
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
Score: 0.034
-
Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. J Clin Endocrinol Metab. 2016 11; 101(11):4195-4204.
Score: 0.034
-
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
Score: 0.034
-
Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites. J Am Heart Assoc. 2016 05 13; 5(5).
Score: 0.033
-
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15; 117(12):1928-33.
Score: 0.033
-
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun; 10(3):635-645.e1.
Score: 0.033
-
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun; 10(3):556-67.
Score: 0.032
-
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
Score: 0.031
-
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015 May 01; 115(9):1212-21.
Score: 0.031
-
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun; 9(3):377-83.
Score: 0.030
-
Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
Score: 0.029
-
Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Vasc Med. 2014 Feb; 19(1):33-41.
Score: 0.028
-
Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
Score: 0.028
-
Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
Score: 0.027
-
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
Score: 0.027
-
Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
Score: 0.027
-
Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013 Apr; 44(4):961-7.
Score: 0.027
-
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol. 2013 Feb 15; 111(4):506-9.
Score: 0.026
-
Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
Score: 0.025
-
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012 Mar; 163(3):515-21, 521.e1-3.
Score: 0.025
-
Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. Circ J. 2012; 76(4):950-6.
Score: 0.025
-
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. J Clin Lipidol. 2012 May-Jun; 6(3):235-43.
Score: 0.024
-
Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
Score: 0.024
-
Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
Score: 0.024
-
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
Score: 0.024
-
Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J. 2012 Jan; 33(2):183-90.
Score: 0.024
-
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
Score: 0.023
-
Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and long-term development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2011 May 15; 107(10):1504-9.
Score: 0.023
-
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011 Feb; 25(1):59-67.
Score: 0.023
-
Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011 Feb; 32(4):459-68.
Score: 0.023
-
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010 Apr 13; 55(15):1600-7.
Score: 0.022
-
Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010 Apr; 28(2):80-6.
Score: 0.022
-
Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
Score: 0.021
-
Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery? Tex Heart Inst J. 2009; 36(6):540-5.
Score: 0.020
-
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
Score: 0.020
-
Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery? Am J Cardiol. 2008 Nov 01; 102(9):1235-9.
Score: 0.020
-
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19; 52(8):626-32.
Score: 0.019
-
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
Score: 0.019
-
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008 May 13; 117(19):2458-66.
Score: 0.019
-
Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2008 Oct; 200(2):322-8.
Score: 0.019
-
Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J. 2008; 35(4):388-94.
Score: 0.019
-
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
Score: 0.019
-
How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
Score: 0.018
-
Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends? Crit Pathw Cardiol. 2007 Jun; 6(2):41-5.
Score: 0.018
-
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar 01; 99(5):673-80.
Score: 0.017
-
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May; 151(5):975.e1-9.
Score: 0.017
-
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28; 165(21):2479-84.
Score: 0.016
-
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
Score: 0.016
-
Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005 Jul; 51(7):1102-9.
Score: 0.016
-
Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005 Dec; 183(2):301-7.
Score: 0.015
-
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 Mar; 149(3):464-73.
Score: 0.015
-
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
Score: 0.015
-
Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
Score: 0.015
-
Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events. EBioMedicine. 2025 Feb; 112:105551.
Score: 0.015
-
Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
Score: 0.015
-
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. Int J Cardiol. 2025 Feb 15; 421:132916.
Score: 0.015
-
Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004 Nov 15; 94(10):1249-54.
Score: 0.015
-
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004 Nov; 26(11):1855-64.
Score: 0.015
-
Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses. Eur J Endocrinol. 2024 Oct 29; 191(5):523-534.
Score: 0.015
-
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004 Sep 15; 94(6):795-7.
Score: 0.015
-
Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. Vasc Med. 2024 12; 29(6):632-639.
Score: 0.015
-
Comparing Cardiovascular Risk Classification of U.S. Adults According to Pooled Cohort Equations and PREVENT Equations: Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. Ann Intern Med. 2024 Oct; 177(10):1444-1448.
Score: 0.015
-
Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
Score: 0.015
-
Global burden of cardiovascular disease attributable to smoking, 1990-2019: an analysis of the 2019 Global Burden of Disease Study. Eur J Prev Cardiol. 2024 Jul 23; 31(9):1123-1131.
Score: 0.015
-
Associations of Ambulatory Blood Pressure Measurements With High-Sensitivity Troponin and Natriuretic Peptide Levels in SPRINT. Am J Hypertens. 2024 07 15; 37(8):571-579.
Score: 0.015
-
Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
Score: 0.015
-
High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT. Hypertension. 2024 Sep; 81(9):1956-1965.
Score: 0.015
-
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul; 58(7):653-8.
Score: 0.015
-
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15; 93(12):1487-94.
Score: 0.015
-
Associations of mid-to-late-life inflammation with late-life mobility and the influences of chronic comorbidities, race, and social determinants of health: The Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2024 Aug; 72(8):2434-2445.
Score: 0.015
-
Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 06 11; 331(22):1898-1909.
Score: 0.015
-
Individual and Joint Associations of High-Sensitivity Troponin I and High-Sensitivity Troponin T with Cardiac Phenotypes and Outcomes in the General Population: An Analysis From the Dallas Heart Study. J Am Heart Assoc. 2024 Jul 02; 13(13):e034549.
Score: 0.015
-
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004 Jun; 89(6):2697-703.
Score: 0.015
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
Score: 0.015
-
Association of High-Density Lipoprotein Parameters and Risk of Heart?Failure: A Multicohort Analysis. JACC Heart Fail. 2024 Jul; 12(7):1242-1253.
Score: 0.014
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.014
-
A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication. J Am Coll Cardiol. 2024 May 28; 83(21):2080-2088.
Score: 0.014
-
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024 05 16; 390(19):1781-1792.
Score: 0.014
-
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
Score: 0.014
-
Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2024 Mar 19; 13(6):e031607.
Score: 0.014
-
Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271.
Score: 0.014
-
Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases. J Natl Med Assoc. 2024 Jun; 116(3):258-270.
Score: 0.014
-
Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis. J Am Coll Cardiol. 2024 02 06; 83(5):577-591.
Score: 0.014
-
Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther. 2004 Jan; 18(1):67-75.
Score: 0.014
-
Novel Size-Based High-Density Lipoprotein Subspecies and Incident Vascular Events. J Am Heart Assoc. 2023 11 07; 12(21):e031160.
Score: 0.014
-
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
Score: 0.014
-
Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses. Ann Intern Med. 2023 09; 176(9):1221-1234.
Score: 0.014
-
Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023 10 05; 389(14):1273-1285.
Score: 0.014
-
Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 01; 91(9):1134-6.
Score: 0.013
-
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20; 107(19):2409-15.
Score: 0.013
-
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
Score: 0.013
-
Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023 03 01; 8(3):222-230.
Score: 0.013
-
Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002 Nov; 4(6):407-14.
Score: 0.013
-
Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC). Clin Chem. 2022 10 06; 68(10):1272-1280.
Score: 0.013
-
Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
Score: 0.013
-
Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
Score: 0.013
-
Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 06 07; 11(11):e024870.
Score: 0.013
-
Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2022 05 03; 11(9):e023238.
Score: 0.013
-
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022 04 05; 11(7):e024999.
Score: 0.013
-
Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022 03 11; 29(2):e53-e64.
Score: 0.012
-
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022 03 15; 11(6):e024176.
Score: 0.012
-
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
Score: 0.012
-
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
Score: 0.012
-
Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 12 15; 161:42-50.
Score: 0.012
-
Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
Score: 0.012
-
The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. J Am Coll Cardiol. 2021 11 16; 78(20):2019-2021.
Score: 0.012
-
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021 11 07; 42(42):4324-4332.
Score: 0.012
-
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 11 30; 144(22):1750-1759.
Score: 0.012
-
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021 12 07; 144(23):1845-1855.
Score: 0.012
-
Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
Score: 0.012
-
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin?Therapy. J Am Coll Cardiol. 2021 09 14; 78(11):1114-1123.
Score: 0.012
-
Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
Score: 0.012
-
Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 11 01; 158:45-52.
Score: 0.012
-
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
Score: 0.012
-
Duration of Diabetes and Incident?Heart?Failure: The ARIC (Atherosclerosis Risk In Communities) Study. JACC Heart Fail. 2021 08; 9(8):594-603.
Score: 0.012
-
Supplemental Association of Clonal Hematopoiesis With Incident Heart?Failure. J Am Coll Cardiol. 2021 07 06; 78(1):42-52.
Score: 0.012
-
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
Score: 0.012
-
High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2021 07; 44(7):1657-1663.
Score: 0.012
-
Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia. Am J Med. 2021 08; 134(8):992-1001.e4.
Score: 0.012
-
Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. Circulation. 2021 06 15; 143(24):2370-2383.
Score: 0.012
-
Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
Score: 0.012
-
Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
Score: 0.012
-
Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
Score: 0.012
-
Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
Score: 0.012
-
Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001 Feb; 23(2):177-92.
Score: 0.012
-
Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
Score: 0.011
-
Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study. JAMA Cardiol. 2021 01 01; 6(1):79-86.
Score: 0.011
-
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
Score: 0.011
-
Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
Score: 0.011
-
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2021 01 05; 143(1):33-44.
Score: 0.011
-
Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000 Nov 01; 36(5):1572-8.
Score: 0.011
-
Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. J Clin Endocrinol Metab. 2020 10 01; 105(10).
Score: 0.011
-
Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000 Oct 01; 86(7):759-63.
Score: 0.011
-
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
Score: 0.011
-
Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
Score: 0.011
-
Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol. 2020 08 18; 76(7):781-793.
Score: 0.011
-
High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care. 2020 10; 43(10):e144-e146.
Score: 0.011
-
Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
Score: 0.011
-
Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. J Am Heart Assoc. 2020 08 04; 9(15):e015410.
Score: 0.011
-
Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study. Arterioscler Thromb Vasc Biol. 2020 09; 40(9):2322-2331.
Score: 0.011
-
Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. Am J Med. 2020 12; 133(12):1424-1432.e1.
Score: 0.011
-
Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020 08 18; 142(7):657-669.
Score: 0.011
-
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
Score: 0.011
-
Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. Am J Med. 2020 11; 133(11):1293-1301.e1.
Score: 0.011
-
Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. J Am Heart Assoc. 2020 05 18; 9(10):e014885.
Score: 0.011
-
Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. Am J Med. 2020 09; 133(9):e508-e511.
Score: 0.011
-
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
Score: 0.011
-
Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2020 03 03; 9(5):e013560.
Score: 0.011
-
Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020 Jan 28; 323(4):329-338.
Score: 0.011
-
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study. Circulation. 2020 03 24; 141(12):957-967.
Score: 0.011
-
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000 Jan; 35(1):89-95.
Score: 0.011
-
Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2019 12 31; 188(12):2146-2155.
Score: 0.011
-
Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Sci Rep. 2019 12 27; 9(1):20168.
Score: 0.011
-
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
Score: 0.011
-
Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. Circ Cardiovasc Imaging. 2019 12; 12(12):e009535.
Score: 0.011
-
Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 03; 221:60-66.
Score: 0.011
-
Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nat Commun. 2019 Nov 12; 10(1):5121.
Score: 0.011
-
Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019 12 17; 140(25):2076-2088.
Score: 0.011
-
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 02 04; 141(5):367-375.
Score: 0.011
-
Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiol. 2019 10 01; 4(10):997-1006.
Score: 0.011
-
Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17?180 Individuals. Circ Res. 2019 09 27; 125(8):773-782.
Score: 0.010
-
High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
Score: 0.010
-
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
Score: 0.010
-
Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. Am Heart J. 2019 10; 216:62-73.
Score: 0.010
-
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
Score: 0.010
-
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. Am J Epidemiol. 2019 Jun 01; 188(6):1033-1054.
Score: 0.010
-
Metabolomic Pattern Predicts Incident Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2019 07; 39(7):1475-1482.
Score: 0.010
-
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
Score: 0.010
-
Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 07 15; 124(2):245-252.
Score: 0.010
-
Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet. 2019 Apr; 51(4):636-648.
Score: 0.010
-
Effects of Icosapent Ethyl on Total?Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019 06 11; 73(22):2791-2802.
Score: 0.010
-
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 03 14; 380(11):1022-1032.
Score: 0.010
-
Sleep apnea and galectin-3: possible sex-specific relationship. Sleep Breath. 2019 Dec; 23(4):1107-1114.
Score: 0.010
-
Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. JAMA Cardiol. 2019 01 01; 4(1):51-58.
Score: 0.010
-
Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
Score: 0.010
-
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2019 03; 282:52-56.
Score: 0.010
-
Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
Score: 0.010
-
Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018 11 01; 103(5):691-706.
Score: 0.010
-
Effect of Evolocumab on Coronary?Plaque Composition. J Am Coll Cardiol. 2018 10 23; 72(17):2012-2021.
Score: 0.010
-
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
Score: 0.010
-
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 09 01; 3(9):806-814.
Score: 0.010
-
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
Score: 0.010
-
Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
Score: 0.010
-
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
Score: 0.010
-
Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998 May; 18(5):723-31.
Score: 0.010
-
Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2018 07; 274:86-93.
Score: 0.010
-
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
Score: 0.009
-
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
Score: 0.009
-
Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
Score: 0.009
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.009
-
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 02 01; 3(2):164-168.
Score: 0.009
-
Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study. Circulation. 2018 05 15; 137(20):2142-2151.
Score: 0.009
-
Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
Score: 0.009
-
SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. Am J Prev Med. 2018 02; 54(2):229-236.
Score: 0.009
-
Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. Am Heart J. 2018 03; 197:62-69.
Score: 0.009
-
Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2018 01; 268:63-67.
Score: 0.009
-
Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 02 15; 121(4):430-436.
Score: 0.009
-
Weight History and Subclinical Myocardial Damage. Clin Chem. 2018 01; 64(1):201-209.
Score: 0.009
-
Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study. Neurology. 2017 Nov 28; 89(22):2262-2270.
Score: 0.009
-
Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
Score: 0.009
-
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH? patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
Score: 0.009
-
Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018 01; 93(1):252-259.
Score: 0.009
-
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
Score: 0.009
-
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
Score: 0.009
-
Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2017 Oct; 192:19-25.
Score: 0.009
-
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis. 2017 Aug; 263:137-144.
Score: 0.009
-
Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clin Rheumatol. 2017 Sep; 36(9):2121-2128.
Score: 0.009
-
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017 07; 5(7):534-543.
Score: 0.009
-
Physical Activity, Obesity, and Subclinical?Myocardial Damage. JACC Heart Fail. 2017 05; 5(5):377-384.
Score: 0.009
-
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
Score: 0.009
-
Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. Circulation. 2017 05 30; 135(22):2119-2132.
Score: 0.009
-
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
Score: 0.009
-
Serum vitamin D and change in lipid levels over 5?y: The Atherosclerosis Risk in Communities study. Nutrition. 2017 Jun; 38:85-93.
Score: 0.009
-
BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
Score: 0.009
-
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
Score: 0.009
-
Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. JACC Heart Fail. 2017 01; 5(1):56-63.
Score: 0.009
-
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 12 13; 316(22):2373-2384.
Score: 0.009
-
Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 12 06; 68(22):2488-2490.
Score: 0.009
-
High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2017 Feb; 40(2):261-269.
Score: 0.009
-
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Am J Cardiol. 2017 Feb 01; 119(3):397-403.
Score: 0.009
-
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
Score: 0.009
-
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
Score: 0.009
-
Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
Score: 0.009
-
Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016 10; 4(10):840-9.
Score: 0.009
-
Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control. J Am Coll Cardiol. 2016 10 18; 68(16):1713-1722.
Score: 0.008
-
Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
Score: 0.008
-
Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
Score: 0.008
-
Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). Am J Cardiol. 2016 Nov 01; 118(9):1399-1404.
Score: 0.008
-
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016 Sep-Oct; 10(5):1223-9.
Score: 0.008
-
Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiol. 2016 08 01; 1(5):519-28.
Score: 0.008
-
Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
Score: 0.008
-
Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
Score: 0.008
-
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 09; 125:57-64.
Score: 0.008
-
Accuracy of the Atherosclerotic Cardiovascular Risk Equation in?a?Large?Contemporary, Multiethnic?Population. J Am Coll Cardiol. 2016 05 10; 67(18):2118-2130.
Score: 0.008
-
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1580-90.
Score: 0.008
-
Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
Score: 0.008
-
Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996 Apr 01; 93(7):1334-8.
Score: 0.008
-
Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2016 06; 18(6):629-37.
Score: 0.008
-
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
Score: 0.008
-
Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem. 2016 Jun; 49(9):657-662.
Score: 0.008
-
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
Score: 0.008
-
The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
Score: 0.008
-
The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. Am J Epidemiol. 2016 Mar 01; 183(5):452-61.
Score: 0.008
-
Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One. 2016; 11(2):e0148765.
Score: 0.008
-
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. Am J Cardiovasc Drugs. 2016 Feb; 16(1):55-65.
Score: 0.008
-
N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016 Feb 16; 133(7):631-8.
Score: 0.008
-
Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016 May; 39(5):677-85.
Score: 0.008
-
Increased expression of ICAM-1 in a case of accelerated coronary artery disease after heart transplantation. Tex Heart Inst J. 1996; 23(4):293-5.
Score: 0.008
-
Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clin Chem. 2015 Dec; 61(12):1524-31.
Score: 0.008
-
Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. Respir Res. 2015 Oct 16; 16:126.
Score: 0.008
-
Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation. 2015 Nov 24; 132(21):1979-89.
Score: 0.008
-
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
Score: 0.008
-
Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 2015 Oct 06; 132(14):1329-37.
Score: 0.008
-
Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2015 Oct; 242(2):625-9.
Score: 0.008
-
Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Nov; 170(5):961-7.
Score: 0.008
-
High-Sensitivity Cardiac Troponin T and Risk of Hypertension. Circulation. 2015 Sep 01; 132(9):825-33.
Score: 0.008
-
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
Score: 0.008
-
Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85.
Score: 0.008
-
Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem. 2015 Jul; 61(7):938-47.
Score: 0.008
-
Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015 Aug; 170(2):380-9.
Score: 0.008
-
Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. Int J Cardiol. 2015; 187:651-7.
Score: 0.008
-
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun; 240(2):490-6.
Score: 0.008
-
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
Score: 0.008
-
Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
Score: 0.008
-
Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov Disord. 2015 Apr; 30(4):552-9.
Score: 0.008
-
Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014 Dec 30; 64(25):2743-9.
Score: 0.008
-
The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015 Apr; 62(4):841-7.
Score: 0.008
-
sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015 Mar; 29(2):180-5.
Score: 0.008
-
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014 Nov 27; 371(22):2072-82.
Score: 0.007
-
FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015 Apr; 8(4):493-494.
Score: 0.007
-
High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
Score: 0.007
-
Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2015 Apr; 65(4):550-8.
Score: 0.007
-
Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014 Dec; 2(6):600-7.
Score: 0.007
-
High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015 Jan; 169(1):31-8.e3.
Score: 0.007
-
Development of chagas cardiac manifestations among Texas blood donors. Am J Cardiol. 2015 Jan 01; 115(1):113-7.
Score: 0.007
-
Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
Score: 0.007
-
Relation between playing position and coronary artery calcium scores in retired National Football League players. Am J Cardiol. 2014 Dec 15; 114(12):1836-40.
Score: 0.007
-
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2465-72.
Score: 0.007
-
Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One. 2014; 9(9):e107340.
Score: 0.007
-
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014 Nov; 37(11):3114-20.
Score: 0.007
-
Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014 Oct 14; 130(16):1374-82.
Score: 0.007
-
Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant. 2015 Jan; 30(1):77-83.
Score: 0.007
-
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
Score: 0.007
-
Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014 Aug; 34(8):1770-7.
Score: 0.007
-
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014 Dec 07; 35(46):3277-86.
Score: 0.007
-
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
Score: 0.007
-
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
Score: 0.007
-
Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014 Jul; 37(7):402-7.
Score: 0.007
-
Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014 Apr 15; 63(14):1441-8.
Score: 0.007
-
Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014 Feb 06; 94(2):233-45.
Score: 0.007
-
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr; 15(4):380-8.
Score: 0.007
-
The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515.
Score: 0.007
-
Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med. 2013 Dec 15; 188(12):1460-5.
Score: 0.007
-
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
Score: 0.007
-
APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions. Genetics. 2013 Dec; 195(4):1397-405.
Score: 0.007
-
Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Oct; 31(5):291-7.
Score: 0.007
-
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26; 128(22):2395-403.
Score: 0.007
-
Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol. 2013 Oct 01; 178(7):1076-84.
Score: 0.007
-
Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
Score: 0.007
-
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J. 2013 Nov; 34(41):3182-90.
Score: 0.007
-
Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
Score: 0.007
-
The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. Am J Epidemiol. 2013 Aug 01; 178(3):401-9.
Score: 0.007
-
Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study. Thromb Res. 2013 Jul; 132(1):44-6.
Score: 0.007
-
Application of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetes. J Am Soc Echocardiogr. 2013 Aug; 26(8):901-909.e1.
Score: 0.007
-
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013 Jun; 45(6):1043-50.
Score: 0.007
-
Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol. 2013 Nov-Dec; 7(6):661-70.
Score: 0.007
-
Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013 Jun; 34(24):1818-25.
Score: 0.007
-
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013 May; 21(5):944-50.
Score: 0.007
-
Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
Score: 0.007
-
sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013 Jun; 62(6):2116-21.
Score: 0.007
-
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb; 13(1):37-46.
Score: 0.007
-
Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013 Mar; 8(3):434-42.
Score: 0.007
-
Association of genome-wide variation with highly sensitive cardiac troponin-T levels in European Americans and Blacks: a meta-analysis from atherosclerosis risk in communities and cardiovascular health studies. Circ Cardiovasc Genet. 2013 Feb; 6(1):82-8.
Score: 0.007
-
Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013 Feb; 23(2):66-73.
Score: 0.007
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
Score: 0.007
-
Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75.
Score: 0.007
-
Association between statins and infections after coronary artery bypass grafting. Int J Cardiol. 2013 Sep 20; 168(1):117-20.
Score: 0.006
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
Score: 0.006
-
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov-Dec; 6(6):565-72.
Score: 0.006
-
Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
Score: 0.006
-
Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012 May; 59(5):653-62.
Score: 0.006
-
Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012 Jan 31; 59(5):484-9.
Score: 0.006
-
Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012 Jul; 27(7):2839-47.
Score: 0.006
-
Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis. Int J Cardiol. 2013 Jul 15; 167(1):180-4.
Score: 0.006
-
Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012 Feb; 5(1):155-62.
Score: 0.006
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.006
-
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 01; 365(22):2078-87.
Score: 0.006
-
Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):73-80.
Score: 0.006
-
Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2012 Jan; 43(1):103-8.
Score: 0.006
-
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012 Jan; 33(2):238-51.
Score: 0.006
-
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet. 2011 Sep 11; 43(10):940-7.
Score: 0.006
-
Segmental analysis of carotid arterial strain using speckle-tracking. J Am Soc Echocardiogr. 2011 Nov; 24(11):1276-1284.e5.
Score: 0.006
-
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
Score: 0.006
-
Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011 Oct; 162(4):725-732.e1.
Score: 0.006
-
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 01; 108(5):682-90.
Score: 0.006
-
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
Score: 0.006
-
The editor's roundtable: JUPITER follow-up. Am J Cardiol. 2011 May 15; 107(10):1549-57.
Score: 0.006
-
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul; 96(7):2236-47.
Score: 0.006
-
Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011 Jun; 161(6):1140-6.
Score: 0.006
-
Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
Score: 0.006
-
Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem. 2011 Jun; 57(6):891-7.
Score: 0.006
-
Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
Score: 0.006
-
Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. Circ J. 2011; 75(6):1378-85.
Score: 0.006
-
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
Score: 0.006
-
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011 Jun; 27(6):1119-29.
Score: 0.006
-
Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood. 2011 May 12; 117(19):5224-30.
Score: 0.006
-
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
Score: 0.006
-
A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Nov; 33(11):2297-303.
Score: 0.006
-
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging. 2010 Jul; 3(4):398-404.
Score: 0.005
-
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44.
Score: 0.005
-
Intercellular adhesion molecule-1 G241R polymorphism predicts risk of incident ischemic stroke: Atherosclerosis Risk in Communities study. Stroke. 2010 May; 41(5):1038-40.
Score: 0.005
-
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
Score: 0.005
-
Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc Med. 2010 Jun; 15(3):171-9.
Score: 0.005
-
Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010 May; 30(5):1034-42.
Score: 0.005
-
Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol. 2010 Mar-Apr; 4(2):105-112.e1.
Score: 0.005
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.005
-
Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet. 2009 Oct 30; 10:111.
Score: 0.005
-
Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
Score: 0.005
-
Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Jan; 33(1):197-9.
Score: 0.005
-
Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989 Jul 07; 262(1):53-6.
Score: 0.005
-
Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009 Jul; 102(1):179-80.
Score: 0.005
-
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
Score: 0.005
-
Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets. 2009 May; 20(3):199-205.
Score: 0.005
-
Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009 Jun; 2(3):279-85.
Score: 0.005
-
Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res. 2009 Aug; 50(8):1685-91.
Score: 0.005
-
The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord. 2009 Jan 27; 9:3.
Score: 0.005
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15; 103(4):515-22.
Score: 0.005
-
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009 Feb 01; 103(3):369-74.
Score: 0.005
-
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
Score: 0.005
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
Score: 0.005
-
APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum Mol Genet. 2008 Jul 01; 17(13):2039-46.
Score: 0.005
-
Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. 2008 May; 21(5):533-8.
Score: 0.005
-
Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol. 2008 Feb 01; 101(3):401-6.
Score: 0.005
-
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008 Feb 15; 101(4):490-6.
Score: 0.005
-
Delayed recovery of severely "stunned" myocardium with the support of a left ventricular assist device after coronary artery bypass graft surgery. J Am Coll Cardiol. 1987 Sep; 10(3):710-2.
Score: 0.005
-
Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2.
Score: 0.005
-
Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study. J Stud Alcohol Drugs. 2007 Jul; 68(4):485-92.
Score: 0.005
-
Genetic variation and decreased risk for obesity in the Atherosclerosis Risk in Communities Study. Diabetes Obes Metab. 2007 Jul; 9(4):548-57.
Score: 0.005
-
An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5.
Score: 0.004
-
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15; 99(12):1706-1713.
Score: 0.004
-
Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2007 Nov; 195(1):e76-82.
Score: 0.004
-
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008 Feb; 196(2):926-30.
Score: 0.004
-
Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism. 1987 Mar; 36(3):270-6.
Score: 0.004
-
Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis. 2007 Oct; 194(2):e131-40.
Score: 0.004
-
Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia. 2007 Jan; 50(1):36-42.
Score: 0.004
-
Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007 Aug; 193(2):283-91.
Score: 0.004
-
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
Score: 0.004
-
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials. 2006 Dec; 27(6):518-30.
Score: 0.004
-
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 Jul 10; 166(13):1368-73.
Score: 0.004
-
Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol. 2006 Aug 15; 164(4):342-8.
Score: 0.004
-
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 05; 295(13):1556-65.
Score: 0.004
-
Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract. 2006 Mar-Apr; 12(2):159-64.
Score: 0.004
-
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec; 26(24):2664-72.
Score: 0.004
-
P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2006 May; 186(1):74-9.
Score: 0.004
-
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
Score: 0.004
-
Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol. 2005 Feb 01; 95(3):367-72.
Score: 0.004
-
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging. 2004 Nov; 22(9):1249-58.
Score: 0.004
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
Score: 0.004
-
Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study. Biomarkers. 2004 Mar-Apr; 9(2):190-202.
Score: 0.004
-
Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2003 Dec; 171(2):265-72.
Score: 0.004
-
B vitamin status and inflammatory markers. Atherosclerosis. 2003 Jul; 169(1):169-74.
Score: 0.003
-
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
Score: 0.003
-
Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003 Apr 29; 107(16):2102-8.
Score: 0.003
-
Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003 Apr 08; 107(13):1729-32.
Score: 0.003
-
Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 Mar; 34(3):623-31.
Score: 0.003
-
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan 01; 91(1):33-41.
Score: 0.003
-
Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. Thromb Res. 2003; 111(3):171-7.
Score: 0.003
-
Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clin Chem. 2002 Nov; 48(11):1913-8.
Score: 0.003
-
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002 Aug; 43(8):1170-80.
Score: 0.003
-
LPL polymorphism predicts stroke risk in men. Genet Epidemiol. 2002 Mar; 22(3):233-42.
Score: 0.003
-
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 04; 104(10):1108-13.
Score: 0.003
-
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001 Aug 15; 111(3):185-91.
Score: 0.003
-
Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001 May 11; 88(9):969-73.
Score: 0.003
-
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 2001 Feb 15; 154(3):633-40.
Score: 0.003
-
A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
Score: 0.003
-
A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl). 2000; 78(10):562-8.
Score: 0.003
-
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
Score: 0.003
-
Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med. 1999 May 10; 159(9):981-7.
Score: 0.003
-
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999 Apr; 143(2):285-97.
Score: 0.003
-
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
Score: 0.002
-
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
Score: 0.002
-
Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transplant Proc. 1993 Feb; 25(1 Pt 1):233-6.
Score: 0.002
-
Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 1991 Oct; 18(4):926-30.
Score: 0.002
-
Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991 Feb 01; 67(4):243-7.
Score: 0.001